55 research outputs found
Endobronchial Ultrasound in Mediastinal Lymphadenopathy
Currently, endobronchial ultrasound dramatically changed diagnostic approaches for mediastinal lesions, both benign and malignant. Still there is a lack of data regarding the optimal anaesthesia, route of intubation, needle type, and specific clinical situations concerning EBUS in real clinical practice. A short, but clinically oriented, description of EBUS-TBNA and EUS-b-FNA techniques for mediastinal lesions is provided
FUNCTIONAL RESPONSE TO ENDOBRONCHIAL VALVE IMPLANTING TO THOSE SUFFERING FROM PULMONARY DESTRUCTIVE TUBERCULOSIS
Goal ofΒ theΒ study: to investigate the changes in ventilation and gas exchange function of the lungs before and after 1-1.5 months after installation of endobronchial valve (EV) aimed at cavity healing in pulmonary destructive tuberculosis patients.Materials andΒ methods. 74 HIV negative patients in the age from 18 to 61 years old suffering from destructive pulmonary tuberculosis were examined. The changes in the pulmonary ventilation capacity (VC, FEV1 , FEV1 /VC%, PEF, MEF25,75) and blood gases (Π Π°Π2 , Π Π°Π‘Π2, SaΠ2 %) before and in 4-6 weeks after EV installation have been studied.Results. After 1-1.5 months after EV installation no significant changes in the pulmonary ventilation function were found in 62.2% of patients, 43.2% of patients demonstrated no significant changes in gas exchange function and there were certain changes in the remaining patients. Reduction of pulmonary ventilation capacity due to large bronchi obstruction, restrictive changes and pulmonary gas exchange were manifested through reduction of FEV1 in 18.9% (95% CI 11.6-29.3%) of patients, PEF β in 20.3% (95% CI 12.7-30.8%), VC β in 22.9% (95% CI 14.9%-33.8%) and PaO2 β in 32.4% (95% CI 22.9-43.7%) of patients.Reduction of carbonic acid content in blood was observed in 27.0% (95% CI 18.3-38.1%) of patients. The improvement of gas exchange and ventilation function was the following: VC in 14.9% of patients (95% CI 8.5-24.7%), Π Π°Π2 β in 24.3% (95% CI 16.0-35.2%) and SΠ°O2 β in 20.3% (95% CI 12.7-30.8%) of patients. Patients remained stable due to moderate intensity of changes.Frequency of negative and positive functional changes after installation of endobronchial valve for valve bronchial blocking (VBB) varies to some extent depending on the place of EV installation, volume of VBB and dissemination of tuberculous lesions.Lower installation of VBB versus upper one: VC increases more rarely (in 8.3 and 21.6% of patients, p < 0.05 respectively), FEV1 decreases more often (in 41.7 and 13.5% of patients p < 0.05 respectively), VC, PEF, Π Π°Π2 and SΠ°O2 go down more often (p < 0.05).If tuberculous lesions are limited the cases when pulmonary ventilation capacity decreases after EV installation occur more often compared to disseminated tuberculous lesions and the cases when pulmonary ventilation capacity improves were observed only in case of the disseminated disease
ΠΡΠ΅Π½ΠΊΠ° ΡΠΎΡΡΠΎΡΠ½ΠΈΡ Π°Π»ΡΠ²Π΅ΠΎΠ»ΡΡΠ½ΠΎΠ³ΠΎ ΡΡΡΡΠ°ΠΊΡΠ°Π½ΡΠ° Π½Π° ΡΡΠΎΡΠΎΠ½Π΅ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΡΠ±Π΅ΡΠΊΡΠ»Π΅Π·Π½ΠΎΠ³ΠΎ ΠΏΠΎΡΠ΅ΡΡΠ° ΠΈ Π² ΠΊΠΎΠ½ΡΡΠ»Π°ΡΠ΅ΡΠ°Π»ΡΠ½ΠΎΠΌ Π»Π΅Π³ΠΊΠΎΠΌ
Practical interest of the problem is associated with the need of timely detection and correction of surfactant dependent disorders of respiratory function accompanying lung tuberculosis and complicating its course.The aim of this study was to compare surface tension indices, anti-atelectatic function and ultrastructure of surfactant membranes in bilateral broncho-alveolar washings from 84 patients with unilateral pulmonary tuberculosis. Ninetytwo percent of fibro-cavernous tuberculosis patients showed significant changes in surface tension and anti-atelectatic function, destructively changed surfactant membranes both in the affected lung and opposite one. In cases of infiltrative lung tuberculosis 63% of patients demonstrated surface tension and anti-atelectatic function disorders, 89% were revealed to emerge changed surfactant membranes in broncho-alveolar washings from both of lungs. In cases of cavernous and focal tuberculosis functional surfactant disorders were observed only in 42 % of patients in the affected side only; ultrastructure of surfactant membranes varied in both of lungs depending on the expressiveness of destructive and compensatory changes in the surfactant system. Data obtained show surfactant reactions in both of lungs as a response to tubercular infection and could be used for diagnostics and prognosing of respiratory failure .ΠΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ΅ ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΠΏΠΎΠ²Π΅ΡΡ
Π½ΠΎΡΡΠ½ΠΎΠ³ΠΎ Π½Π°ΡΡΠΆΠ΅Π½ΠΈΡ (ΠΠ), ΡΠΎΡΡΠΎΡΠ½ΠΈΡ Π°Π½ΡΠΈΠ°ΡΠ΅Π»Π΅ΠΊΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΠ½ΠΊΡΠΈΠΈ (Π‘ΠΠ€) ΠΈ ΡΠ»ΡΡΡΠ°ΡΡΡΡΠΊΡΡΡΡ ΠΌΠ΅ΠΌΠ±ΡΠ°Π½ ΡΡΡΡΠ°ΠΊΡΠ°Π½ΡΠ° (Π‘) Π² Π±ΠΈΠ»Π°ΡΠ΅ΡΠ°Π»ΡΠ½ΡΡ
Π±ΡΠΎΠ½Ρ
ΠΎΠ°Π»ΡΠ²Π΅ΠΎΠ»ΡΡΠ½ΡΡ
ΡΠΌΡΠ²Π°Ρ
(ΠΠΠ‘) 84 Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΎΠ΄Π½ΠΎΡΡΠΎΡΠΎΠ½Π½ΠΈΠΌ ΡΡΠ±Π΅ΡΠΊΡΠ»Π΅Π·ΠΎΠΌ (Π’) Π»Π΅Π³ΠΊΠΈΡ
. ΠΡΠΈΡΠΈΠ±ΡΠΎΠ·Π½ΠΎ-ΠΊΠ°Π²Π΅ΡΠ½ΠΎΠ·Π½ΠΎΠΌ ΡΡΠ±Π΅ΡΠΊΡΠ»Π΅Π·Π΅ Ρ 92% Π±ΠΎΠ»ΡΠ½ΡΡ
Π²ΡΡΠ²Π»Π΅Π½Ρ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΡΠ΅ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΠΠΈΠ‘ΠΠ€, Π΄Π΅ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎ-ΠΈΠ·ΠΌΠ΅Π½Π΅Π½Π½ΡΠ΅ ΠΌΠ΅ΠΌΠ±ΡΠ°Π½Ρ Π‘ ΠΊΠ°ΠΊ Π½Π° ΡΡΠΎΡΠΎΠ½Π΅ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ, ΡΠ°ΠΊ ΠΈ Π² ΠΊΠΎΠ½ΡΡΠ»Π°ΡΠ΅ΡΠ°Π»ΡΠ½ΠΎΠΌ Π»Π΅Π³ΠΊΠΎΠΌ. ΠΡΠΈ ΠΈΠ½ΡΠΈΠ»ΡΡΡΠ°ΡΠΈΠ²Π½ΠΎΠΌ Π’ Ρ 63% Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΎΡΠΌΠ΅ΡΠ΅Π½Ρ Π½Π°ΡΡΡΠ΅Π½ΠΈΡ ΠΠΠΈΠ‘ΠΠ€, Ρ 89%-ΠΏΠΎΡΠ²Π»Π΅Π½ΠΈΠ΅ Π² ΠΠΠ‘ ΠΈΠ· ΠΎΠ±ΠΎΠΈΡ
Π»Π΅Π³ΠΊΠΈΡ
Π²ΠΈΠ΄ΠΎΠΈΠ·ΠΌΠ΅Π½Π΅Π½Π½ΡΡ
ΠΌΠ΅ΠΌΠ±ΡΠ°Π½ Π‘. ΠΡΠΈ ΠΊΠ°Π²Π΅ΡΠ½ΠΎΠ·Π½ΠΎΠΌ ΠΈ ΠΎΡΠ°Π³ΠΎΠ²ΠΎΠΌ Π’ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠ΅ Π½Π°ΡΡΡΠ΅Π½ΠΈΡ Π‘ ΠΎΡΠΌΠ΅ΡΠ΅Π½Ρ ΡΠΎΠ»ΡΠΊΠΎ Ρ 42% Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΈ ΡΠΎΠ»ΡΠΊΠΎ Π½Π° ΡΡΠΎΡΠΎΠ½Π΅ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ. Π£Π»ΡΡΡΠ°ΡΡΡΡΠΊΡΡΡΠ° ΠΌΠ΅ΠΌΠ±ΡΠ°Π½ Π‘ Π²Π°ΡΡΠΈΡΠΎΠ²Π°Π»Π° Π² ΠΎΠ±ΠΎΠΈΡ
Π»Π΅Π³ΠΊΠΈΡ
Π² Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΡΡΠΈ Π΄Π΅ΡΡΡΡΠΊΡΠΈΠ²Π½ΡΡ
ΠΈ ΠΊΠΎΠΌΠΏΠ΅Π½ΡΠ°ΡΠΎΡΠ½ΡΡ
ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠΉ ΡΡΡΡΠ°ΠΊΡΠ°Π½ΡΠ½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ. ΠΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΠΎΡΡΠ°ΠΆΠ°ΡΡ ΡΠ΅Π°ΠΊΡΠΈΡ Π‘ ΠΎΠ±ΠΎΠΈΡ
Π»Π΅Π³ΠΊΠΈΡ
Π² ΠΎΡΠ²Π΅Ρ Π½Π° ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ ΡΡΠ±Π΅ΡΠΊΡΠ»Π΅Π·Π½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ
ΠΠ΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ Ρ ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ ΠΠΠ£/Π¨ΠΠ£-Π’Π Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ ΡΠΈΡΠΎΠΊΠΎΠΉ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΡΡΠΈ ΠΠΠ§-ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ
The review used 61 literature sources to discuss 13 publications devoted to safety of treatment of HIV-associated drug-resistant tuberculosis using basic and new regimens of chemotherapy. According to the literature, no additive toxic eο¬ects were detected during treatment with anti-tuberculosis and antiretroviral drugs. According to the literature data, no additive toxic eο¬ect was found during treatment with anti-tuberculosis and antiretroviral drugs. In conditions of high prevalence of HIV, the pharmacovigilance of drug interactions in combination therapy is particularly relevant since HIV can indirectly increase the number of ADRs not only due to cross-toxicity but also severe immunosuppression, development of immune system recovery syndrome, opportunistic infections, a characteristic intoxication syndrome, a low index body weight and individual characteristics of patients in this category.Π ΠΎΠ±Π·ΠΎΡΠ΅ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ 61 Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΠ½ΡΠΉ ΠΈΡΡΠΎΡΠ½ΠΈΠΊ Π΄Π»Ρ ΠΎΠ±ΡΡΠΆΠ΄Π΅Π½ΠΈΡ 13 ΠΏΡΠ±Π»ΠΈΠΊΠ°ΡΠΈΠΉ, ΠΏΠΎΡΠ²ΡΡΠ΅Π½Π½ΡΡ
ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ΅ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΠΠ§-Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎ-ΡΡΡΠΎΠΉΡΠΈΠ²ΠΎΠ³ΠΎ ΡΡΠ±Π΅ΡΠΊΡΠ»Π΅Π·Π° Ρ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ΠΌ Π±Π°Π·ΠΎΠ²ΡΡ
ΠΈ Π½ΠΎΠ²ΡΡ
ΡΠ΅ΠΆΠΈΠΌΠΎΠ² Ρ
ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ. Π‘ΠΎΠ³Π»Π°ΡΠ½ΠΎ Π΄Π°Π½Π½ΡΠΌ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ, Π°Π΄Π΄ΠΈΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΡΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ Π½Π° ΡΠΎΠ½Π΅ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΡΠΎΡΠΈΠ²ΠΎΡΡΠ±Π΅ΡΠΊΡΠ»Π΅Π·Π½ΡΠΌΠΈ ΠΈ Π°Π½ΡΠΈΡΠ΅ΡΡΠΎΠ²ΠΈΡΡΡΠ½ΡΠΌΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°ΠΌΠΈ Π½Π΅ Π²ΡΡΠ²Π»Π΅Π½ΠΎ. Π ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΡΠΈΡΠΎΠΊΠΎΠΉ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΡΡΠΈ ΠΠΠ§ ΠΎΡΠΎΠ±ΠΎ Π°ΠΊΡΡΠ°Π»ΡΠ½ΡΠΌ ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΠ°ΡΠΌΠ°ΠΊΠΎΠ½Π°Π΄Π·ΠΎΡ Π·Π° Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΠΌ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ΠΌ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ, ΠΏΠΎΡΠΊΠΎΠ»ΡΠΊΡ ΠΠΠ§ ΠΌΠΎΠΆΠ΅Ρ ΠΊΠΎΡΠ²Π΅Π½Π½ΠΎ ΡΠ²Π΅Π»ΠΈΡΠΈΡΡ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ Π½Π΅ΠΆΠ΅Π»Π°ΡΠ΅Π»ΡΠ½ΡΡ
ΡΠ΅Π°ΠΊΡΠΈΠΉ (ΠΠ ) Π½Π΅ ΡΠΎΠ»ΡΠΊΠΎ ΠΈΠ·-Π·Π° ΠΏΠ΅ΡΠ΅ΠΊΡΠ΅ΡΡΠ½ΠΎΠΉ ΡΠΎΠΊΡΠΈΡΠ½ΠΎΡΡΠΈ, Π½ΠΎ ΠΈ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΠΉ ΠΈΠΌΠΌΡΠ½ΠΎΡΡΠΏΡΠ΅ΡΡΠΈΠΈ, ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ° Π²ΠΎΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ ΠΈΠΌΠΌΡΠ½Π½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ, ΠΎΠΏΠΏΠΎΡΡΡΠ½ΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ, Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠ½ΠΎΠ³ΠΎ ΠΈΠ½ΡΠΎΠΊΡΠΈΠΊΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ°, Π½ΠΈΠ·ΠΊΠΎΠ³ΠΎ ΠΈΠ½Π΄Π΅ΠΊΡΠ° ΠΌΠ°ΡΡΡ ΡΠ΅Π»Π° ΠΈ ΠΈΠ½Π΄ΠΈΠ²ΠΈΠ΄ΡΠ°Π»ΡΠ½ΡΡ
ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ Π±ΠΎΠ»ΡΠ½ΡΡ
Π₯ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ ΡΡΠ±Π΅ΡΠΊΡΠ»Π΅Π·Π° Π² Π ΠΎΡΡΠΈΠΈ β ΠΈΡΡΠΎΡΠΈΡ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠ°Π΅ΡΡΡ
.
ΠΠ ΠΠ’ΠΠΠΠ’Π£ΠΠΠ ΠΠ£ΠΠΠΠΠ«Π ΠΠΠ’ΠΠΠΠΠ’ΠΠ Π ΠΠ€ΠΠΠΠΠ’ΠΠ: ΠΠΠ Π‘ΠΠΠΠ’ΠΠΠ« ΠΠΠΠΠΠ§ΠΠ‘ΠΠΠΠ ΠΠ‘ΠΠΠΠ¬ΠΠΠΠΠΠΠ―
Anti-tuberculosis chemotherapy makes a main component of therapy and involves the long-term treatment with the optimal combination of drugs.Β Tuberculosis incidence has been noted to be high in the risk groups (those receiving immunosuppressive therapy, people living with HIV, etc.);Β such patients are treated for their main disease in addition to anti-tuberculosis chemotherapy. A large number of drugs used simultaneously inΒ treatment regimens can reduce patient's adherence to treatment, deteriorate drug tolerance and increase the frequency of adverse reactions. UsingΒ slow-release drugs within treatment regimens is one of the ways to reduce polypragmasy. One of them is rifapentine, recommended in the RussianΒ Federation for the treatment of latent tuberculosis infection in patients with HIV infection.The review presents information about the efficacy, tolerability and safety of rifapentine within treatment regimens for active and latent tuberculosisΒ infection.ΠΡΠΎΡΠΈΠ²ΠΎΡΡΠ±Π΅ΡΠΊΡΠ»Π΅Π·Π½Π°Ρ Ρ
ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΎΡΠ½ΠΎΠ²Π½ΡΠΌ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠΎΠΌ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΈ ΠΏΡΠ΅Π΄ΠΏΠΎΠ»Π°Π³Π°Π΅Ρ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ΅ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΎΠΏΡΠΈΠΌΠ°Π»ΡΠ½ΠΎΠΉΒ ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ². ΠΡΡΠΎΠΊΠ°Ρ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΡ ΡΡΠ±Π΅ΡΠΊΡΠ»Π΅Π·ΠΎΠΌ ΠΎΡΠΌΠ΅ΡΠ°Π΅ΡΡΡ Π² Π³ΡΡΠΏΠΏΠ°Ρ
ΡΠΈΡΠΊΠ° (Π»ΠΈΡΠ°, ΠΏΠΎΠ»ΡΡΠ°ΡΡΠΈΠ΅ ΠΈΠΌΠΌΡΠ½ΠΎ-ΡΡΠΏΡΠ΅ΡΡΠΈΠ²Π½ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ, Π»ΠΈΡΠ°, ΠΆΠΈΠ²ΡΡΠΈΠ΅ Ρ ΠΠΠ§, ΠΈ Ρ. Π΄.), ΡΠ°ΠΊΠΈΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ, ΠΏΠΎΠΌΠΈΠΌΠΎ ΠΏΡΠΎΡΠΈΠ²ΠΎΡΡΠ±Π΅ΡΠΊΡΠ»Π΅Π·Π½ΠΎΠΉ Ρ
ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ, ΠΏΠΎΠ»ΡΡΠ°ΡΡ Π»Π΅ΡΠ΅Π½ΠΈΠ΅Β ΠΏΠΎ ΠΎΡΠ½ΠΎΠ²Π½ΠΎΠΌΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ. ΠΠ΄Π½ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠ΅ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ Π² ΡΡ
Π΅ΠΌΠ°Ρ
Π»Π΅ΡΠ΅Π½ΠΈΡ Π±ΠΎΠ»ΡΡΠΎΠ³ΠΎ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π° ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² ΠΌΠΎΠΆΠ΅Ρ ΡΠ½ΠΈΠΆΠ°ΡΡ ΠΏΡΠΈΠ²Π΅ΡΠΆΠ΅Π½Π½ΠΎΡΡΡ ΠΊ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°, ΡΡ
ΡΠ΄ΡΠ°ΡΡ ΠΏΠ΅ΡΠ΅Π½ΠΎΡΠΈΠΌΠΎΡΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² ΠΈ ΡΠ²Π΅Π»ΠΈΡΠΈΠ²Π°ΡΡ ΡΠ°ΡΡΠΎΡΡ Π½Π΅ΠΆΠ΅Π»Π°ΡΠ΅Π»ΡΠ½ΡΡ
ΠΏΠΎΠ±ΠΎΡΠ½ΡΡ
ΡΠ΅Π°ΠΊΡΠΈΠΉ. ΠΠ΄Π½ΠΈΠΌ ΠΈΠ· ΠΏΡΡΠ΅ΠΉΒ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΡ ΠΏΠΎΠ»ΠΈΠΏΡΠ°Π³ΠΌΠ°Π·ΠΈΠΈ ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ Π² ΡΡ
Π΅ΠΌΠ°Ρ
Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² ΠΏΡΠΎΠ»ΠΎΠ½Π³ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ. ΠΠ΄Π½ΠΈΠΌ ΠΈΠ· Π½ΠΈΡ
ΡΠ²Π»ΡΠ΅ΡΡΡΒ ΡΠΈΡΠ°ΠΏΠ΅Π½ΡΠΈΠ½, ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄ΠΎΠ²Π°Π½Π½ΡΠΉ Π² Π Π€ Π΄Π»Ρ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π»Π°ΡΠ΅Π½ΡΠ½ΠΎΠΉ ΡΡΠ±Π΅ΡΠΊΡΠ»Π΅Π·Π½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΠΠ§-ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠ΅ΠΉ.Β Π ΠΎΠ±Π·ΠΎΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ ΡΠ²Π΅Π΄Π΅Π½ΠΈΡ ΠΎΠ± ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ, ΠΎ ΠΏΠ΅ΡΠ΅Π½ΠΎΡΠΈΠΌΠΎΡΡΠΈ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΡΠΈΡΠ°ΠΏΠ΅Π½ΡΠΈΠ½ Π² ΡΡ
Π΅ΠΌΠ°Ρ
Π»Π΅ΡΠ΅Π½ΠΈΡΒ Π°ΠΊΡΠΈΠ²Π½ΠΎΠΉ ΠΈ Π»Π°ΡΠ΅Π½ΡΠ½ΠΎΠΉ ΡΡΠ±Π΅ΡΠΊΡΠ»Π΅Π·Π½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ
Π Π΅ΡΠΈΠ΄ΠΈΠ² ΡΡΠ±Π΅ΡΠΊΡΠ»Π΅Π·Π° Π»Π΅Π³ΠΊΠΈΡ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΠΈΠ·ΠΎΠ½ΠΈΠ°Π·ΠΈΠ΄-ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΡΠΌ ΡΡΠ±Π΅ΡΠΊΡΠ»Π΅Π·ΠΎΠΌ
The objective: to study the incidence of relapses over a two-year period after successful completion of chemotherapy in patients with isoniazid-resistant tuberculosis (Hr TB), to determine the risk factors for relapses in this cohort.Subjects and Methods. The medical records of 1860 Hr-TB patients who started treatment in 2015 in TB hospitals in 18 regions of the Russian Federation were retrospectively studied. Of these, 1271 (68.3 Β± 1.08%) patients successfully completed a full course of chemotherapy, which were divided into two groups depending on the presence/absence of relapse in the next two years.Results. Tuberculosis relapse was observed in 131/1271 (10.31%; CI 8,75β12,10%) (R+ Group) patients, the remaining 1140 patients(Rβ Group) developed no relapse. For R+ and Rβ Groups, the first episode of the disease (FED) was analyzed, for R+ Group, the episode of the disease recurrence detection (DRD) was also analyzed. The risk factors for relapse development include the following parameters that were available in patients during first episode of the disease: unemployment at working age (OR=1,98; 95% CI [1,36β2,88]), diabetes mellitus or chronic alcohol addiction (OR=3,93; 95% CI [2,13β7,26%] and OR=2,25; 95% CI [1,02β5,01]), lung tissue decay OR=2,01; 95% CI [1,31β3,07], and drug resistance of Mycobacterium tuberculosis (H+Ag+Fq) (OR=7,26; 95% CI [3,90β10,62]).With the disease recurrence detection, out of 131 patients of R+ Group, the positive results of the sputum test was recorded only in 117 (89,3%) patients, 41/131 (31,3%) patients developed a different clinical form of tuberculosis versus the first episode of the disease, and in 12/41 ( 29,3%) or 12/131 (9,2%) patients, the disease was more severe. 44/117 (37,6%) patients had been already resistant to rifampicin. It means they had developed MDR TB before the relapse was detected.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ: ΠΈΠ·ΡΡΠΈΡΡ ΡΠ°ΡΡΠΎΡΡ ΡΠ΅ΡΠΈΠ΄ΠΈΠ²ΠΎΠ² Π·Π° Π΄Π²ΡΡ
Π»Π΅ΡΠ½ΠΈΠΉ ΠΏΠ΅ΡΠΈΠΎΠ΄ ΠΏΠΎΡΠ»Π΅ ΡΡΠΏΠ΅ΡΠ½ΠΎΠ³ΠΎ Π·Π°Π²Π΅ΡΡΠ΅Π½ΠΈΡ Ρ
ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΈΠ·ΠΎΠ½ΠΈΠ°Π·ΠΈΠ΄-ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΡΠΌ ΡΡΠ±Π΅ΡΠΊΡΠ»Π΅Π·ΠΎΠΌ (Hr Π’Π), ΠΎΠΏΡΠ΅Π΄Π΅Π»ΠΈΡΡ ΡΠ°ΠΊΡΠΎΡΡ ΡΠΈΡΠΊΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΠ΅ΡΠΈΠ΄ΠΈΠ²ΠΎΠ² Π² Π΄Π°Π½Π½ΠΎΠΉ ΠΊΠΎΠ³ΠΎΡΡΠ΅.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π Π΅ΡΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎ ΠΈΠ·ΡΡΠ΅Π½Ρ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΈΠ΅ Π΄ΠΎΠΊΡΠΌΠ΅Π½ΡΡ 1860 Π±ΠΎΠ»ΡΠ½ΡΡ
Hr Π’Π, Π½Π°ΡΠ°Π²ΡΠΈΡ
Π»Π΅ΡΠ΅Π½ΠΈΠ΅ Π² 2015 Π³ΠΎΠ΄Ρ Π² ΠΏΡΠΎΡΠΈΠ²ΠΎΡΡΠ±Π΅ΡΠΊΡΠ»Π΅Π·Π½ΡΡ
ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ°Ρ
18 ΡΠ΅Π³ΠΈΠΎΠ½ΠΎΠ² Π Π€. ΠΠ· Π½ΠΈΡ
ΡΡΠΏΠ΅ΡΠ½ΠΎ Π·Π°Π²Π΅ΡΡΠΈΠ»ΠΈ ΠΏΠΎΠ»Π½ΡΠΉ ΠΊΡΡΡ Ρ
ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ 1271 (68,3Β±1,08%) ΠΏΠ°ΡΠΈΠ΅Π½Ρ, ΠΊΠΎΡΠΎΡΡΠ΅ Π±ΡΠ»ΠΈ ΡΠ°ΡΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Ρ Π² Π΄Π²Π΅ Π³ΡΡΠΏΠΏΡ Π² Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ Π½Π°Π»ΠΈΡΠΈΡ/ΠΎΡΡΡΡΡΡΠ²ΠΈΡ ΡΠ΅ΡΠΈΠ΄ΠΈΠ²Π° Π² ΠΏΠΎΡΠ»Π΅Π΄ΡΡΡΠΈΠ΅ Π΄Π²Π° Π³ΠΎΠ΄Π°.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π Π΅ΡΠΈΠ΄ΠΈΠ² ΡΡΠ±Π΅ΡΠΊΡΠ»Π΅Π·Π° Π½Π°Π±Π»ΡΠ΄Π°Π»ΡΡ Ρ 131/1271 (10,31%; ΠΠ 8,75β12,10%) (Π³ΡΡΠΏΠΏΠ° Β«Π +Β») ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², Ρ ΠΎΡΡΠ°Π»ΡΠ½ΡΡ
1140 (Π³ΡΡΠΏΠΏΠ° Β«Π βΒ») β ΡΠ΅ΡΠΈΠ΄ΠΈΠ²Π° Π½Π΅ Π±ΡΠ»ΠΎ. ΠΠ»Ρ Π³ΡΡΠΏΠΏ Β«Π +Β» ΠΈ ««РβΒ» Π°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π»ΡΡ ΠΏΠ΅ΡΠ²ΡΠΉ ΡΠΏΠΈΠ·ΠΎΠ΄ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ (ΠΠΠ), Π΄Π»Ρ Π³ΡΡΠΏΠΏΡ Β«Π +Β» Π΅ΡΠ΅ ΠΈ ΡΠΏΠΈΠ·ΠΎΠ΄ Π²ΡΡΠ²Π»Π΅Π½ΠΈΡ ΡΠ΅ΡΠΈΠ΄ΠΈΠ²Π° Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ (ΠΠ Π). Π ΡΠ°ΠΊΡΠΎΡΠ°ΠΌ ΡΠΈΡΠΊΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΠ΅ΡΠΈΠ΄ΠΈΠ²Π° ΠΎΡΠ½Π΅ΡΠ΅Π½Ρ ΡΠ»Π΅Π΄ΡΡΡΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ, ΠΈΠΌΠ΅Π²ΡΠΈΠ΅ΡΡ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π½Π° ΠΌΠΎΠΌΠ΅Π½Ρ ΠΠΠ: ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ ΡΠ°Π±ΠΎΡΡ Π² ΡΡΡΠ΄ΠΎΡΠΏΠΎΡΠΎΠ±Π½ΠΎΠΌ Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ (ΠΠ¨=1,98; 95%ΠΠ [1,36β2,88]), Π½Π°Π»ΠΈΡΠΈΠ΅ ΡΠ°Ρ
Π°ΡΠ½ΠΎΠ³ΠΎ Π΄ΠΈΠ°Π±Π΅ΡΠ° ΠΈΠ»ΠΈ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π°Π»ΠΊΠΎΠ³ΠΎΠ»ΠΈΠ·ΠΌΠ° (ΠΠ¨=3,93; 95%ΠΠ [2,13β7,26%] ΠΈ ΠΠ¨=2,25; 95%ΠΠ [1,02β5,01]), ΡΠ°ΡΠΏΠ°Π΄ Π»Π΅Π³ΠΎΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ ΠΠ¨=2,01; 95%ΠΠ [1,31β3,07]; ΠΠ£ ΠΠΠ’ (H+Ag+Fq) (ΠΠ¨=7,26; 95%ΠΠ [3,90β10,62]).ΠΡΠΈ ΠΠ Π ΠΈΠ· 131 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Π³ΡΡΠΏΠΏΡ Β«Π +Β» Π±Π°ΠΊΡΠ΅ΡΠΈΠΎΠ²ΡΠ΄Π΅Π»Π΅Π½ΠΈΠ΅ Π±ΡΠ»ΠΎ Π·Π°ΡΠΈΠΊΡΠΈΡΠΎΠ²Π°Π½ΠΎ ΡΠΎΠ»ΡΠΊΠΎ Ρ 117 (89,3%), Ρ 41/131 (31,3%) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° ΡΠ°Π·Π²ΠΈΠ»Π°ΡΡ Π΄ΡΡΠ³Π°Ρ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΠΎΡΠΌΠ° ΡΡΠ±Π΅ΡΠΊΡΠ»Π΅Π·Π°, ΡΠ΅ΠΌ ΠΏΡΠΈ ΠΠΠ, ΠΈ Ρ 12/41 (29,3%) ΠΈΠ»ΠΈ 12/131 (9,2%) ΠΎΠ½Π° Π±ΡΠ»Π° Π±ΠΎΠ»Π΅Π΅ ΡΡΠΆΠ΅Π»ΠΎΠΉ. Π£ 44/117 (37,6%) ΡΠΆΠ΅ Π½Π°Π±Π»ΡΠ΄Π°Π»Π°ΡΡ ΡΡΡΠΎΠΉΡΠΈΠ²ΠΎΡΡΡ ΠΠΠ’ ΠΊ ΡΠΈΡΠ°ΠΌΠΏΠΈΡΠΈΠ½Ρ, ΡΠΎ Π΅ΡΡΡ ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΠΠΠ£ ΠΠΠ’ ΠΏΡΠΎΠΈΠ·ΠΎΡΠ»ΠΎ Π΄ΠΎ Π²ΡΡΠ²Π»Π΅Π½ΠΈΡ ΡΠ΅ΡΠΈΠ΄ΠΈΠ²Π°
ΠΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΠ΅ ΡΠ°Π·Π»ΠΈΡΠΈΡ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ Π»ΠΎΠΊΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΈ Π³Π΅Π½Π΅ΡΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΠΎΠΉ ΡΠΎΡΠΌΠ°ΠΌΠΈ ΡΠ°ΡΠΊΠΎΠΌΡ ΠΠ°ΠΏΠΎΡΠΈ
The objective: to evaluate clinical and laboratory parameters in local and generalized forms of Kaposi sarcoma (KS) in HIV infected patients to detect predictors of generalized forms of the disease.Subjects and methods. Case histories of 58 HIV infected patients with KS at the age from 28 to 80 years old were respectively analyzed; they all received treatment in National Medical Research Center of Phthisiopulmonology and Infectious Diseases of the Russian Ministry of Health in 2018-2020. Cases were divided into 2 groups depending on KS manifestations. LF group (local form of KS, n = 28) included the patients with skin lesions; GF group (generalized form of KS, n = 30) included patients with skin lesions and one or several lesions in the other sites: the mucous membrane of gastrointestinal tract, the mucous membrane of tracheobronchial tree, and lung parenchyma.Results. Patients with the generalized form of KS had a higher frequency of skin lesions on the body (pΟ2 = 0.036), face (pΟ2 = 0.033), and multiple sites (pΟ2 = 0.018). Patients from both groups had low CD4+ count, but it was more severe in GF group (pΟ2 = 0.027) with a significant increase of the viral load (pΟ2 = 0.047). The predictors of the generalized form of KS are the following: the presence of specific lesions on the skin of body, face and multiple localizations, CD4 level below 125 cells/mcL, increase in the viral load above 5.3log10 copies/ml, reduction of erythrocytes level below 3.1 Γ 1012 cells/L. Among 24 patients with KS who had 4-6 predictors, 19 (79.2%) had the generalized form. Among KS patients with not a single predictor, there were no cases of generalized form, as well as there were no cases of local forms among patients who had 5 and 6 predictors.Π¦Π΅Π»Ρ: ΠΎΡΠ΅Π½ΠΈΡΡ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΠ΅ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΡ ΠΏΡΠΈ Π»ΠΎΠΊΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΈ Π³Π΅Π½Π΅ΡΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΠΎΠΉ ΡΠΎΡΠΌΠ°Ρ
ΡΠ°ΡΠΊΠΎΠΌΡ ΠΠ°ΠΏΠΎΡΠΈ (Π‘Π) Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΠΠ§-ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠ΅ΠΉ Π΄Π»Ρ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΠΏΡΠ΅Π΄ΠΈΠΊΡΠΎΡΠΎΠ² Π³Π΅Π½Π΅ΡΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΡΡ
ΡΠΎΡΠΌ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π Π΅ΡΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎ ΠΏΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Ρ ΠΈΡΡΠΎΡΠΈΠΈ Π±ΠΎΠ»Π΅Π·Π½ΠΈ 58 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΠΠ§-ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠ΅ΠΉ ΠΈ Π‘Π Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ ΠΎΡ 28 Π΄ΠΎ 80 Π»Π΅Ρ, ΠΏΠΎΠ»ΡΡΠ°Π²ΡΠΈΡ
Π»Π΅ΡΠ΅Π½ΠΈΠ΅ Π² Π€ΠΠΠ£ Β«ΠΠΠΠ¦ Π€ΠΠΒ» ΠΠΈΠ½Π·Π΄ΡΠ°Π²Π° Π ΠΎΡΡΠΈΠΈ Π² 2018-2020 Π³Π³. Π‘ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½Ρ Π΄Π²Π΅ Π³ΡΡΠΏΠΏΡ Π² Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΠΉ Π‘Π. Π Π³ΡΡΠΏΠΏΡ ΠΠ€ (Π»ΠΎΠΊΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½Π°Ρ ΡΠΎΡΠΌΠ° Π‘Π, n = 28) Π²ΠΊΠ»ΡΡΠ΅Π½Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ Ρ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΠ΅ΠΌ ΠΊΠΎΠΆΠΈ, Π² Π³ΡΡΠΏΠΏΡ ΠΠ€ (Π³Π΅Π½Π΅ΡΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½Π°Ρ ΡΠΎΡΠΌΠ° Π‘Π, n = 30) β Ρ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ΠΌ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΠΉ ΠΊΠΎΠΆΠΈ Ρ ΠΎΠ΄Π½ΠΈΠΌ ΠΈΠ»ΠΈ Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΈΠΌΠΈ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡΠΌΠΈ Π΄ΡΡΠ³ΠΈΡ
Π»ΠΎΠΊΠ°Π»ΠΈΠ·Π°ΡΠΈΠΉ: ΡΠ»ΠΈΠ·ΠΈΡΡΠ°Ρ ΠΎΠ±ΠΎΠ»ΠΎΡΠΊΠ° ΠΆΠ΅Π»ΡΠ΄ΠΎΡΠ½ΠΎ-ΠΊΠΈΡΠ΅ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ°ΠΊΡΠ°, ΡΠ»ΠΈΠ·ΠΈΡΡΠ°Ρ ΠΎΠ±ΠΎΠ»ΠΎΡΠΊΠ° ΡΡΠ°Ρ
Π΅ΠΎΠ±ΡΠΎΠ½Ρ
ΠΈΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π΄Π΅ΡΠ΅Π²Π°, ΠΏΠ°ΡΠ΅Π½Ρ
ΠΈΠΌΠ° Π»Π΅Π³ΠΊΠΈΡ
.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π£ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π³Π΅Π½Π΅ΡΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΠΎΠΉ ΡΠΎΡΠΌΠΎΠΉ Π‘Π ΠΎΡΠΌΠ΅ΡΠ°Π»ΠΎΡΡ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠ΅ ΡΠ°ΡΡΠΎΡΡ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ ΠΊΠΎΠΆΠΈ Π½Π° ΡΡΠ»ΠΎΠ²ΠΈΡΠ΅ (pΟ2 = 0,036), Π»ΠΈΡΠ΅ (pΟ2 = 0,033), Π° ΡΠ°ΠΊΠΆΠ΅ ΠΌΠ½ΠΎΠΆΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΡΡΡ Π»ΠΎΠΊΠ°Π»ΠΈΠ·Π°ΡΠΈΠΉ (pΟ2 = 0,018). ΠΠ»Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΎΠ±Π΅ΠΈΡ
Π³ΡΡΠΏΠΏ Π±ΡΠ»ΠΎ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠ½ΠΎ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ ΡΡΠΎΠ²Π½Ρ CD4+-Π»ΠΈΠΌ- ΡΠΎΡΠΈΡΠΎΠ², Π½ΠΎ Π±ΠΎΠ»Π΅Π΅ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΠ΅ Π² Π³ΡΡΠΏΠΏΠ΅ ΠΠ€ (pΟ2 = 0,027) ΠΏΡΠΈ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΌ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠΈ Π²ΠΈΡΡΡΠ½ΠΎΠΉ Π½Π°Π³ΡΡΠ·ΠΊΠΈ (pΟ2 = 0,047). ΠΡΠ΅Π΄ΠΈΠΊΡΠΎΡΠ°ΠΌΠΈ Π³Π΅Π½Π΅ΡΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΠΎΠΉ ΡΠΎΡΠΌΡ Π‘Π ΡΠ²Π»ΡΡΡΡΡ: Π½Π°Π»ΠΈΡΠΈΠ΅ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ Π½Π° ΠΊΠΎΠΆΠ΅ ΡΡΠ»ΠΎΠ²ΠΈΡΠ°, Π»ΠΈΡΠ° ΠΈ ΠΌΠ½ΠΎΠΆΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
Π»ΠΎΠΊΠ°Π»ΠΈΠ·Π°ΡΠΈΠΉ, ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ ΡΡΠΎΠ²Π½Ρ CD4 Π’-Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² Π½ΠΈΠΆΠ΅ 125 ΠΊΠ»/ΠΌΠΊΠ», ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ Π²ΠΈΡΡΡΠ½ΠΎΠΉ Π½Π°Π³ΡΡΠ·ΠΊΠΈ Π²ΡΡΠ΅ 5,3 log10 ΠΊΠΎΠΏΠΈΠΉ/ΠΌΠ», ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ ΡΡΠΎΠ²Π½Ρ ΡΡΠΈΡΡΠΎΡΠΈΡΠΎΠ² Π½ΠΈΠΆΠ΅ 3,1 Γ 1012 ΠΊΠ»/Π». Π‘ΡΠ΅Π΄ΠΈ 24 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π‘Π, ΠΈΠΌΠ΅Π²ΡΠΈΡ
4-6 ΠΏΡΠ΅Π΄ΠΈΠΊΡΠΎΡΠΎΠ², 19 (79,2%) Π±ΡΠ»ΠΈ Ρ Π³Π΅Π½Π΅ΡΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΠΎΠΉ ΡΠΎΡΠΌΠΎΠΉ. Π‘ΡΠ΅Π΄ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π‘Π, Π½Π΅ ΠΈΠΌΠ΅Π²ΡΠΈΡ
Π½ΠΈ ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΠΏΡΠ΅Π΄ΠΈΠΊΡΠΎΡΠ°, ΡΠ»ΡΡΠ°Π΅Π² Π³Π΅Π½Π΅ΡΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΠΎΠΉ ΡΠΎΡΠΌΡ Π½Π΅ Π±ΡΠ»ΠΎ, ΡΠ°ΠΊΠΆΠ΅ ΠΊΠ°ΠΊ Π½Π΅ Π±ΡΠ»ΠΎ ΡΠ»ΡΡΠ°Π΅Π² Π»ΠΎΠΊΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΠΎΠΉ ΡΠΎΡΠΌΡ ΡΡΠ΅Π΄ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΈΠΌΠ΅Π²ΡΠΈΡ
5 ΠΈ 6 ΠΏΡΠ΅Π΄ΠΈΠΊΡΠΎΡΠΎΠ²
- β¦